1![Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso](https://www.pdfsearch.io/img/b9e795e5fd8be86ca7fa0b39dbba34d7.jpg) | Add to Reading ListSource URL: engelmanlab.med.harvard.eduLanguage: English - Date: 2013-05-21 15:55:24
|
---|
2![Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav](https://www.pdfsearch.io/img/5fe1e2e872e34bc8689936802b0cca4f.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
3![Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S](https://www.pdfsearch.io/img/23315319e0e6ab8409732bdb66460d32.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:22
|
---|
4![Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I](https://www.pdfsearch.io/img/f2edba1b703eb36b34072d7f4ded7f54.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:11
|
---|
5![Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside](https://www.pdfsearch.io/img/ea7e0a57ead0c5e1fe795ddfcd1c9524.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:24
|
---|
6![ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P](https://www.pdfsearch.io/img/c5e756c483bd9b39f54c6028d7480e61.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2015-01-27 14:49:56
|
---|
7![](https://www.pdfsearch.io/img/a9fba69c0c1187137d8f36ad121f8b95.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:09
|
---|
8![Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572) Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)](https://www.pdfsearch.io/img/51152d62f200fd67b0efcd447d1ac610.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:21
|
---|
9![Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C](https://www.pdfsearch.io/img/97d3adc47fc6c54010acb9a2355d8fcc.jpg) | Add to Reading ListSource URL: shionogi616.tew-staging.comLanguage: English - Date: 2014-11-03 11:26:18
|
---|
10![](https://www.pdfsearch.io/img/63ac2b28b48f30d59aee5fdab1abfbb9.jpg) | Add to Reading ListSource URL: www.england.nhs.ukLanguage: English - Date: 2015-01-14 06:19:30
|
---|